The Journal of Clinical Endocrinology & Metabolism · 2008 · 95 citations · 16 references
MedicineOncologyPharmacologyEndocrine OncologyMolecular ImagingMolecular OncologyAdrenal ImagingCytochrome P450 EnzymesCytochrome P450-mediated MetabolismEndocrine Tumor ImagingMolecular Imaging In OncologyTumor ImagingCell BiodistributionCytochrome P450 Drug MetabolismCytochrome P450 Enzyme ActivityCytochrome P450 IsoenzymesIodine-123 Metaiodobenzylguanidine ScintigraphyMetastatic Adrenal TumorsMetomidate ImagingMolecular Imaging Tracers
BACKGROUND: Due to advances in conventional imaging, adrenal tumors are detected with increasing frequency. However, conventional imaging provides only limited information on the origin of these lesions, which represent a wide range of different pathological entities. New specific imaging methods would therefore be of great clinical value. We, therefore, studied the potential of iodometomidate (IMTO) as tracer for molecular imaging of cytochrome P450 family 11B (Cyp11B) enzymes. METHODS: Inhibition of Cyp11B1 and Cyp11B2 by IMTO, etomidate, metomidate, and fluoroetomidate was investigated in NCI-h295 cells and in Y1 cells stably expressing hsCyp11B1 or hsCyp11B2. Pharmacokinetics and biodistribution after iv injection of [(123/125)I]IMTO were analyzed in mice in biodistribution experiments and by small-animal single-photon emission computed tomography (SPECT). Furthermore, four patients with known adrenal tumors (two metastatic adrenal adenocarcinomas, one bilateral adrenocortical adenoma, and one melanoma metastasis) were investigated with [(123)I]iodometomidate-SPECT. RESULTS: In cell culture experiments, all compounds potently inhibited both Cyp11B1 and Cyp11B2. Adrenals showed high and specific uptake of [(123/125)I]IMTO and were excellently visualized in mice. In patients, adrenocortical tissue showed high and specific tracer uptake in both primary tumor and metastases with short investigation time and low radiation exposure, whereas the non-adrenocortical tumor did not exhibit any tracer uptake. CONCLUSION: We have successfully completed the development of an in vivo detection system of adrenal Cyp11B enzymes by [(123)I]IMTO scintigraphy in both experimental animals and humans. Our findings suggest that [(123)I]IMTO is a highly specific radiotracer for imaging of adrenocortical tissue. Due to the general availability of SPECT technology, we anticipate that [(123)I]IMTO scintigraphy may become a widely used tool to characterize adrenal lesions.
16
Incidentally discovered adrenal masses
R. T. Kloos · Endocrine Reviews · 1995 · 272 citations
Medicine, Endocrinology, Pathology +10
Joakim Hennings, Örjan Lindhe, Mats Bergström et al. · The Journal of Clinical Endocrinology & Metabolism · 2006 · 139 citations · Full text
Scintigraphic evaluation of clinically silent adrenal masses.
Milton D. Gross, Brahm Shapiro, Isaac R. Francis et al. · PubMed · 1994 · 125 citations